NASDAQ:TLX Telix Pharmaceuticals (TLX) Stock Price, News & Analysis $9.90 -2.21 (-18.22%) As of 09:32 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Telix Pharmaceuticals Stock (NASDAQ:TLX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Telix Pharmaceuticals alerts:Sign Up Key Stats Today's Range$9.95▼$9.9550-Day Range$10.82▼$17.1552-Week Range$9.95▼$30.36Volume126,416 shsAverage Volume47,743 shsMarket Capitalization$3.35 billionP/E RatioN/ADividend YieldN/APrice Target$22.33Consensus RatingBuy Company Overview Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. Read More Receive TLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TLX Stock News HeadlinesUS FDA seeks more information on Telix Pharma's diagnostic drug for kidney cancerAugust 27 at 9:58 PM | reuters.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLXAugust 27 at 10:00 AM | prnewswire.comWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your IRA could be at risk. Here’s how to prepare.August 28 at 2:00 AM | Reagan Gold Group (Ad)Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens BermanAugust 26 at 4:22 PM | globenewswire.comTelix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment ConferenceAugust 26 at 7:00 AM | globenewswire.comWedbush Reduces Earnings Estimates for Telix PharmaceuticalsAugust 26 at 2:21 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLXAugust 25 at 12:26 PM | globenewswire.comTLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law FirmAugust 25 at 3:20 AM | prnewswire.comSee More Headlines TLX Stock Analysis - Frequently Asked Questions How have TLX shares performed this year? Telix Pharmaceuticals' stock was trading at $15.40 at the start of the year. Since then, TLX shares have decreased by 21.4% and is now trading at $12.10. When did Telix Pharmaceuticals IPO? Telix Pharmaceuticals (TLX) raised $202 million in an initial public offering (IPO) on Friday, June 14th 2024. The company issued 17,000,000 shares at $11.87 per share. Who are Telix Pharmaceuticals' major shareholders? Telix Pharmaceuticals' top institutional investors include Pier Capital LLC (0.06%), Russell Investments Group Ltd. (0.02%), Jane Street Group LLC (0.01%) and Vanguard Personalized Indexing Management LLC (0.01%). How do I buy shares of Telix Pharmaceuticals? Shares of TLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today8/27/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TLX Previous SymbolNASDAQ:TLX CIK2007191 Webwww.telixpharma.com Phone61-3-9093-3855FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Telix Pharmaceuticals$22.33 High Price Target$23.00 Low Price Target$22.00 Potential Upside/Downside+84.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.99 Current Ratio2.78 Quick Ratio2.66 Sales & Book Value Annual Sales$516.72 million Price / Sales7.92 Cash Flow$0.11 per share Price / Cash Flow109.82 Book Value$1.12 per share Price / Book10.80Miscellaneous Outstanding Shares338,400,000Free FloatN/AMarket Cap$4.09 billion OptionableN/A BetaN/A 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:TLX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telix Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Telix Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.